Zymeworks logo

ZymeworksNYSE: ZYME

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

28 April 2017

Next earnings report:

06 March 2025

Last dividends:

N/A

Next dividends:

N/A
$1.02 B
-14%vs. 3y high
74%vs. sector
-vs. 3y high
-vs. sector
-18%vs. 3y high
67%vs. sector
-60%vs. 3y high
82%vs. sector

Price

after hours | Tue, 19 Nov 2024 22:45:38 GMT
$14.77-$0.14(-0.94%)

Dividend

No data over the past 3 years
$16.00 M$65.39 M
$16.00 M-$29.85 M

Analysts recommendations

Institutional Ownership

ZYME Latest News

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors
globenewswire.com05 November 2024 Sentiment: POSITIVE

Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in treatment of advanced cancers including ovarian, endometrial, and non-small cell lung cancers Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in treatment of advanced cancers including ovarian, endometrial, and non-small cell lung cancers

Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab
seekingalpha.com04 November 2024 Sentiment: POSITIVE

The PDUFA date for potential approval of Zanidatamab for the treatment of patients with 2nd-line biliary tract cancer set for November 29th of 2024. Progression-free survival data from the phase 3 HERIZON-GEA-01 study using Zanidatamab + chemotherapy plus or minus tislelizumab for treatment of patients with 1st-line GEA is expected in Q2 of 2025. Zanidatamab is being developed in collaboration with two big pharmaceutical companies, which are Jazz Pharmaceuticals and BeiGene.

Zymeworks Announces Participation in Upcoming Investor Conferences
globenewswire.com29 October 2024 Sentiment: POSITIVE

VANCOUVER, British Columbia, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
globenewswire.com25 October 2024 Sentiment: POSITIVE

VANCOUVER, British Columbia, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced new preclinical data for Zymeworks' antibody-drug conjugate (ADC) candidates ZW220 and ZW251 in presentations at the European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR) Conference taking place in Barcelona on October 23-25, 2024.

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
globenewswire.com21 October 2024 Sentiment: POSITIVE

VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the first patient has been dosed in the first-in-human Phase 1 trial (NCT06523803) to evaluate the safety and tolerability of the investigational therapy ZW171 in the treatment of advanced or metastatic ovarian cancer, NSCLC, and other MSLN-expressing cancers.

Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024
globenewswire.com10 October 2024 Sentiment: POSITIVE

VANCOUVER, British Columbia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its third quarter 2024 financial results after market close on October 31, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on October 31, 2024 at 4:30 pm Eastern Time (ET).

Zymeworks Approaching A Moment Of Truth With Zanidatamab
seekingalpha.com27 September 2024 Sentiment: POSITIVE

ZYME's zanidatamab is under regulatory review for the treatment of second-line HER2-positive biliary tract cancer, with potential US approval in November 2024. Subsequent approval in the same indication could follow in the EU as early as Q2 '25, and in China in H2 '25. A readout from the HERIZON-GEA-01 study of zanidatamab in gastroesophageal adenocarcinoma in Q2 '25 represents a major clinical catalyst for ZYME.

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
globenewswire.com18 September 2024 Sentiment: POSITIVE

Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks' proprietary antibody-drug conjugate development platforms Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks' proprietary antibody-drug conjugate development platforms

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)
globenewswire.com03 September 2024 Sentiment: POSITIVE

VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today reported, as required by the Nasdaq Stock Market Rule 5635(c) (the “Nasdaq Rule”), an equity inducement award to Ms. Leone Patterson, Zymeworks' Executive Vice President and Chief Business and Financial Officer.

Zymeworks Announces Participation in Upcoming Investor Conferences
globenewswire.com22 August 2024 Sentiment: POSITIVE

VANCOUVER, British Columbia, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:

  • 1(current)
  • 2
  • 3

What type of business is Zymeworks?

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

What sector is Zymeworks in?

Zymeworks is in the Healthcare sector

What industry is Zymeworks in?

Zymeworks is in the Biotechnology industry

What country is Zymeworks from?

Zymeworks is headquartered in United States

When did Zymeworks go public?

Zymeworks initial public offering (IPO) was on 28 April 2017

What is Zymeworks website?

https://www.zymeworks.com

Is Zymeworks in the S&P 500?

No, Zymeworks is not included in the S&P 500 index

Is Zymeworks in the NASDAQ 100?

No, Zymeworks is not included in the NASDAQ 100 index

Is Zymeworks in the Dow Jones?

No, Zymeworks is not included in the Dow Jones index

When was Zymeworks the previous earnings report?

No data

When does Zymeworks earnings report?

The next expected earnings date for Zymeworks is 06 March 2025